The histone deacetylase inhibitor trichostatin a sensitizes estrogen receptor α-negative breast cancer cells to tamoxifen

Oncogene

Volumn 23, Issue 9, 2004, Pages 1724-1736

  Jang, Eun Ryoung ^a,b   Lim, Soo Jeong ^a   Lee, Eun Sook ^a   Jeong, Gajin ^b   Kim, Tae You ^c   Bang, Yung Jue ^c   Lee, Jong Soo ^a  

^a National Cancer Center   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

; Er negative breast cancer; Estrogen receptor ; Hdac inhibitor; Tamoxifen responsiveness

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HISTONE DEACETYLASE INHIBITOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TRICHOSTATIN A; ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; HISTONE DEACETYLASE; HYDROXAMIC ACID; MESSENGER RNA; RNA;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIZATION; ESTROGEN RESPONSIVE ELEMENT; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR UPREGULATION; TRANSCRIPTION REGULATION; ACTIVE TRANSPORT; BREAST TUMOR; DNA RESPONSIVE ELEMENT; DRUG ANTAGONISM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; METABOLISM; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RESPONSE ELEMENTS; RNA, MESSENGER; RNA, NEOPLASM; TAMOXIFEN;

EID: 1642339046     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207315     Document Type: Article

References (42)

1. Acevedo ML and Kraus WL. (2003). Mol. Cell. Biol., 23, 335-348.
2. An J, Ribeiro RCJ, Webb P, Gustafsson J-A, Kushner PJ, Baxter JD and Leitman DC. (1999). Proc. Natl. Acad. Sci. USA, 96, 15161-15166.
3. Bieche I, Parfait B, Laurendeau I, Girault I, Vidaud M and Lidereau R. (2001). Oncogene, 20, 8109-8115.
4. Bovenzi V and Momparler RL. (2001). Cancer Chemother. Pharmacol., 48, 71-76.
5. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB. (1987). Cancer Res., 47, 936-942.
6. Brummelkamp TR, Bernards R and Agami R. (2002). Science, 296, 550-553.
7. Chang J, Powles TJ, Allred DC, Ashley SE, Makris A, Gregory RK, Osborne CK and Dowsett M. (2000). Clin. Cancer Res., 6, 616-621.
8. Couse JF and Korach KS. (1999). Endocr. Rev., 20, 358-417.
9. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG and Rosen EM. (2002). Cancer Res., 62, 141-151.
10. Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID and Rosen EM. (1999). Science, 284, 1354-1356.
11. Ghoshal K, Datta J, Majumder S, Bai S, Dong X, Parthun M and Jacob ST. (2002). Mol. Cell. Biol., 22, 8302-8319.
12. Hager GL, Lim CS and Elbi CBaumann CT. (2000). J. Steroid Biochem. Mol. Biol., 30, 249-254.
13. Hall JM and McDonnell DP. (1999). Endocrinology, 140, 5566-5578.
14. Hedden A, Muller V and Jensen EV. (1995). Ann. NY Acad. Sci., 761, 109-120.
15. Jensen EV, Cheng G, Palmieri C, Saji S, Makela S, Van Noorden S, Wahlstrom T, Warner M, Coombes RC and Gustafsson JA. (2001). Proc. Natl. Acad Sci. USA, 98, 15197-15202.
16. Jordan VC. (2001). Ann. NY Acad Sci., 949, 72-79.
17. Jung DJ, Lee SK and Lee JW. (2001). J. Biol. Chem., 276, 37280-37283.
18. Kaaks R, Lukanova A and Kurzer MS. (2002). Cancer Epidemiol. Biomarkers Prev., 11, 1531-1543.
19. Kawata M. (2001). Arch. Histol. Cytol., 64, 353-368.
20. Kim MY, Hsiao S and Kraus WL. (2001). EMBO J., 20, 6084-6094.
21. Kumar R, Wang RA, Mazumdar A, Talukder AH, Mandal M, Yang Z, Bagheri-Yarmand R, Sahin A, Hortobagyi G, Adam L, Barnes CJ and Vadlamudi RK. (2002). Nature, 418, 654-657.
22. Levenson AS, Svoboda KM, Pease KM, Kaiser SA, Chen B, Simons LA, Jovanovic BD, Dyck PA and Jordan VC. (2002). Cancer Res., 62, 4419-4426.
23. Liu M-M, Albaneses C, Anderson CM, Hilty K, Webb P, Uh RM, Price RH, Pestell RG and Kushner PJ. (2002). J. Biol. Chem., 277, 24353-24360.
24. Macaluso M, Cinti C, Russo G, Russo A and Giordano A. (2003). Oncogene, 22, 3511-3517.
25. Mandlekar S and Kong A-N. (2001). Apoptosis, 6, 469-477.
26. Matsuda K, Ochiai I, Nishi M and Kawata M. (2002). Mol. Endocrinol., 16, 2215-2230.
27. Mazumdar A, Wang RA, Mishra SK, Adam L, Bagheri-Yarmand R, Mandal M, Vadlamudi RK and Kumar R. (2001). Nat. Cell Biol., 3, 30-37.
28. McDonnell DP and Norris JD. (2002). Science, 296, 1642-1644.
29. Nilsson S and Gustafsson JA. (2000). Breast Cancer Res., 2, 360-366.
30. Noh EJ and Lee J-S. (2003). Biochem. Biophys. Res. Commun., 310, 267-273.
31. Norris JD, Fan D, Sherk A and McDonnell DP. (2002). Mol. Endocrinol., 16, 459-468.
32. Paech K, Webb P, Kuiper GGJ, Nilsson S, Gustafsson J-A, Kushner PJ and Scanlan TS. (1999). Science, 277, 1508-1510.
33. Palmieri C, Cheng GJ, Saji S, Zelada-Hedman M, Warri A, Weihua Z, Van Noorden S, Wahlstrom T, Coombes RC, Warner M and Gustafsson J-A. (2002). Endocr. Relat. Cancer, 9, 1-13.
34. Park W-C and Jordan VC. (2002). Trends Mol. Med., 8, 82-87.
35. Powles TJ. (2002). Nat. Rev. Cancer, 2, 787-794.
36. Scott GK, Marden C, Xu F, Kirk L and Benz CC. (2002). Mol. Cancer Ther., 1, 385-392.
37. Shi Y, Downes M, Xie W, Kao HY, Ordentlich P, Tsai CC, Hon M and Evans RM. (2001). Genes Dev., 15, 1140-1151.
38. Sun JM, Chen HY and Davie JR. (2001). J. Biol Chem., 276, 49435-49442.
39. Weihua Z, Lathe R, Warner M and Gustafsson JA. (2002). Proc. Natl. Acad. Sci. USA, 99, 13589-13594.
40. Yanagisawa J, Kitagawa H, Yanagida M, Wada O, Ogawa S, Nakagomi M, Oishi H, Yamamoto Y, Nagasawa H, McMahon SB, Cole MD, Tora L, Takahashi N and Kato S. (2002). Mol. Cell, 9, 553-562.
41. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG and Davidson NE. (2000). Cancer Res., 60, 6890-6894.
42. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG and Davidson NE. (2001). Cancer Res., 61, 7025-7029.